Key Updates
British American Tobacco has declined -2.08% since the last report to £4,565, moderating YTD gains to +8.33% from the previous +10.63%. The recent pullback follows a period of strong recovery but remains within the established uptrend. No significant company-specific news emerged during this period, with the decline likely reflecting broader market consolidation after the recent rally. The investment thesis remains intact, supported by the strong full-year 2025 results reported on February 12th, which continue to underpin valuation despite the short-term price weakness.
Current Trend
BAT maintains a positive YTD trajectory at +8.33%, demonstrating resilience despite the recent -2.08% pullback. The stock has established a clear upward trend over the past six months (+10.53%) and one month (+4.32%), with the current price of £4,565 representing a technical consolidation after reaching £4,662 in the previous report. The five-day performance of +0.18% suggests stabilization following the recent decline. Key support appears to be forming around the £4,500-£4,550 range, while resistance from the recent peak at £4,662 remains relevant. The stock continues to trade well above its early-year levels, maintaining substantial gains despite short-term volatility.
Investment Thesis
The investment thesis centers on BAT's successful transformation into a diversified tobacco and nicotine products company, with accelerating contributions from next-generation products. The company delivered exceptional 2025 results with pretax profit surging to £9.86 billion from £3.54 billion, while new categories revenue grew 7% to £3.62 billion. Velo's market share gains in the critical U.S. nicotine pouch market provide a strategic counterweight to declining combustible volumes. The 2% dividend increase to 245.04 pence per share reinforces BAT's commitment to shareholder returns, offering a compelling yield profile. However, the thesis faces headwinds from illicit market pressures in key geographies, particularly the U.S. vape market (70% illegal penetration) and South Africa (75% illicit cigarette market share), which threaten both traditional and new category revenues.
Thesis Status
The investment thesis remains fundamentally sound despite the recent price consolidation. The -2.08% decline appears technical rather than fundamental, occurring without new negative catalysts. The February 12th results exceeded consensus expectations with adjusted operating profit of £11.89 billion versus £11.29 billion forecasted, validating the transformation strategy. Velo's competitive positioning against Philip Morris's Zyn demonstrates execution capability in high-growth segments. However, the decision to close the South African factory highlights the severity of illicit trade challenges, while ongoing U.S. International Trade Commission cases regarding unauthorized vapes remain unresolved with impact unlikely before 2027. The thesis continues to balance strong financial delivery against structural market challenges, with the current price consolidation offering a potentially attractive entry point within the broader uptrend.
Key Drivers
BAT's performance is driven by five critical factors. First, the exceptional 2025 financial results with pretax profit reaching £9.86 billion demonstrate operational excellence and transformation progress. Second, Velo's market share gains in the U.S. against Altria's On! and Philip Morris's Zyn establish competitive positioning in the high-growth nicotine pouch category. Third, potential U.S. import restrictions on unauthorized vapes could reduce the illegal e-cigarette market by approximately one-third, though implementation remains delayed until 2027. Fourth, illicit trade pressures forced the closure of BAT's South African factory, with illegal cigarettes comprising 75% of that market and unauthorized vapes representing 70% of U.S. e-cigarette sales. Fifth, intensifying competitive dynamics from Philip Morris, which exceeded profit expectations and announced $1.6 billion in investments for Zyn and IQOS, create ongoing market share pressures.
Technical Analysis
BAT exhibits a constructive technical structure despite the recent -2.08% decline. The stock established a six-month uptrend channel with support around £4,130 (six-month low implied) and resistance at £4,662 (recent peak). Current price action at £4,565 represents a healthy pullback of approximately 2% from the recent high, testing support in the £4,500-£4,550 zone. The five-day performance of +0.18% suggests consolidation rather than breakdown, with the one-month gain of +4.32% indicating sustained buying interest. Volume patterns (not provided) would be critical to assess whether this represents profit-taking or distribution. The YTD gain of +8.33% positions the stock in the upper quartile of its recent range, with the 200-day moving average (estimated around £4,200-£4,300 based on six-month performance) providing structural support. A break above £4,662 would signal continuation toward £4,800-£4,900, while failure to hold £4,500 could trigger retracement to £4,300-£4,400.
Bull Case
- Exceptional profit growth validates transformation strategy: Pretax profit surged to £9.86 billion in 2025 from £3.54 billion in 2024, with adjusted operating profit of £11.89 billion exceeding consensus forecasts of £11.29 billion, demonstrating successful execution of the next-generation products strategy. Source: Wall Street Journal
- Velo gains competitive ground in critical U.S. nicotine pouch market: BAT's Velo brand captured market share against Philip Morris's Zyn and Altria's On! through higher nicotine strengths and promotional strategies, positioning the company in the fastest-growing tobacco category with significant margin potential. Source: Reuters
- Potential regulatory relief from unauthorized vape imports: U.S. International Trade Commission cases could result in import restrictions eliminating approximately one-third of the illegal e-cigarette market (currently 70% of U.S. vape sales), with full ITC determination expected in March 2026 and potential to restore legitimate market share. Source: Reuters
- Accelerating new categories revenue growth: Revenue from vapor, heated products, and oral pouches increased 7% at constant currencies to £3.62 billion in 2025, demonstrating sustained momentum in higher-margin next-generation products that offset combustible volume declines. Source: Morningstar
- Attractive dividend yield with progressive policy: The board declared a 2% dividend increase to 245.04 pence per share, maintaining BAT's reputation for consistent shareholder returns and providing a defensive income component that supports valuation during market volatility. Source: Wall Street Journal
Bear Case
- Severe illicit trade undermines core markets and forces asset closures: BAT announced closure of its South African factory due to illegal cigarettes comprising 75% of that market, while unauthorized vapes represent 70% of U.S. e-cigarette sales, directly impacting both traditional and new category revenues with no near-term resolution. Source: Bloomberg
- Intensifying competitive pressure from Philip Morris in key growth categories: Philip Morris reported smoke-free revenues of nearly $17 billion serving 43 million consumers and announced $1.6 billion in investments to support Zyn and IQOS growth, with 2026 EPS guidance of 11.1%-13.1% growth demonstrating superior momentum versus BAT. Source: Business Wire
- Delayed regulatory relief on unauthorized vapes pushes benefits to 2027: Despite favorable ITC judge ruling, BAT management stated that any import restrictions on illegal disposable vapes would not materially impact results before 2027 due to long supply chains and existing inventories, prolonging market share erosion. Source: Reuters
- Declining combustible volumes face structural headwinds: Overall group revenue declined 1% to £25.61 billion with a 3.1% foreign exchange headwind, while vape volumes fell nearly 13% in 2025 due to illegal product competition in the U.S. and Canada, indicating pressure on both traditional and transition categories. Source: Bloomberg
- Governance concerns with Chair tenure extension beyond recommended limits: The board extended Chair Luc Jobin's tenure for up to two additional years beyond July 2026, exceeding the U.K. Corporate Governance Code's nine-year recommendation, potentially signaling succession planning challenges or strategic uncertainty. Source: Wall Street Journal